Physician profile
Christopher Eric Majewski
NPI 1013975226
$1,930.27
in general payments reported to CMS, 2019-2025
9 companies · $70.73 in 2025
The $70.73 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.11 · 2023: $23.61 · 2024: $1,818 · 2025: $70.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $929 · Long Term Medical Supply Or Device Loan: $814 · Food and Beverage: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $929.15 |
| Long Term Medical Supply Or Device Loan | $814.08 |
| Food and Beverage | $168.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $814.08 | 2024 | Integra |
| Mid-Atlantic Surgical Systems, LLC | $768.20 | 2024 | |
| Arthrex, INC. | $204.95 | 2024 | |
| Organogenesis INC. | $51.97 | 2023-2025 | Affinity, Puraply |
| Treace Medical Concepts, INC. | $25.95 | 2025 | |
| Stryker Corporation | $18.11 | 2020 | |
| Averitas Pharma INC. | $16.64 | 2024 | Qutenza |
| Convatec INC. | $16.42 | 2025 | |
| Smith+Nephew, INC. | $13.95 | 2024 | Regranex, Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Majewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.